Wire · opportunities
Oneness Biotech Advances SNS851 to Phase 1 Multiple-Ascending Dose Evaluation for ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 30 September 2026 · Fusion42 review
Oneness Biotech has advanced its investigational siRNA therapy SNS851 to the multiple-ascending dose phase of its Phase 1 trial for treating obesity-associated metabolic diseases, aiming to improve metabolic efficiency through a novel mechanism focused on liver mitochondrial activity and energy expenditure. The therapy shows promise both as a monotherapy and combined with GLP-1 treatments, with safety and pharmacokinetics established in healthy volunteers and data from fatty liver disease patients expected in early 2027.
This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 29 Sep 2026 and 30 Sep 2026.
◆ ◆ The Wire takeaway
Your obesity treatment now has a metabolic alternative beyond appetite suppression. Therapeutic strategies combining siRNA drugs like SNS851 with GLP-1 boosters open new routes to durable weight loss and metabolic control.
◆ Coverage
3 sources · first reported 29 Sep 2026 · latest 30 Sep 2026
◆ Related on Wire
◆ Topics